Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Elashoff
Michael Elashoff, Gaithersburg, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20080281526 | Methods For Molecular Toxicology Modeling - The present invention is based on methods of predicting toxicity of test agents and methods of generating toxicity prediction models using algorithms for analyzing quantitative gene expression information. The invention also includes computer systems comprising the toxicity prediction models, as well as methods of using the computer systems by remote users for determining the toxicity of test agents. | 11-13-2008 |
| 20090220970 | MOLECULAR TOXICOLOGY MODELING - The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes. | 09-03-2009 |
| 20110071767 | Hepatotoxicity Molecular Models - The present invention includes methods of predicting hepatotoxicity of test agents and methods of generating hepatotoxicity prediction models using algorithms for analyzing quantitative gene expression information. The invention also includes microarrays, computer systems comprising the toxicity prediction models, as well as methods of using the computer systems by remote users for determining the toxicity of test agents. | 03-24-2011 |
Michael Elashoff, Redwood City, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20120015830 | MICRORNA PROFILES FOR EVALUATING MULTIPLE SCLEROSIS - The present invention provides methods, systems, and kits for evaluating multiple sclerosis (MS) in a patient. Particularly, the invention provides convenient miRNA-based tests for evaluating a patient for MS, including for diagnosing MS, for excluding MS as a diagnosis, for determining the presence of disease activity associated with MS, and for monitoring the course of disease or efficacy of treatment for MS. | 01-19-2012 |
Michael R. Elashoff, Redwood City, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20110015865 | DETERMINATION OF CORONARY ARTERY DISEASE RISK - Markers and methods useful for assessing coronary artery disease in a subject are provided, along with kits for measuring their expression. Also provided are predictive models, based on the markers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples. | 01-20-2011 |
| 20110184712 | PREDICTIVE MODELS AND METHODS FOR DIAGNOSING AND ASSESSING CORONARY ARTERY DISEASE - Biomarkers useful for diagnosing and assessing the extent of coronary artery disease (CAD) are provided, along with kits for measuring their expression. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples. In a preferred embodiment, the biomarkers are organized into clustered groups. The expression level of the biomarkers within a group are highly correlated to each other in normal and disease states. Expression values of genes chosen from each of two, three, four or five of the clustered gene groups, A, B, C, D, E may be used. Alternatively, expression values of genes chosen from the groups are combined into a metagene. Preferred biomarkers include S100A12, S100A8, S100A9, BCL2A1, and F5 (group A); XK, P62, and FECH (group B); TUBB2 (group C); IFNG, PDGFB, VSIG4, and TNF (group D); CSF3R, TLR5, CD46, and NCF1 (group E); S100A12, S100A9, BCL2A1, TXN and CSTA (group I); OLIG1, OLIG2, ADORA3, CLC, and SLC29A1 (group II); and CBS and ARG1 (group IV). | 07-28-2011 |
Michael R. Elashoff, Gaithersburg, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20090197258 | PRIMARY RAT HEPATOCYTE TOXICITY MODELING - The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes. | 08-06-2009 |
Michael R. Elashoff, Germantown, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20080215250 | Molecular toxicology modeling - The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes. | 09-04-2008 |